谷氨酸能神经传递在抑郁症发病机制中的研究进展

神经药理学报 ›› 2014, Vol. 4 ›› Issue (1): 20-24.

谷氨酸能神经传递在抑郁症发病机制中的研究进展

李婧孙建栋苑玉和陈乃宏

1.天然药物活性物质与功能国家重点实验室，新药作用机制研究与药效评价北京市重点实验室，中国医学科学院药物研究所，北京，100050，中国
2.天津中医药大学，天津，300193，中国

出版日期:2014-02-26 发布日期:2014-06-06
通讯作者: 陈乃宏，男，研究员，博士生导师；Tel.: +86-010-63165177，Fax: +86-010-63165177，E-mail: chennh@imm.ac.cn
作者简介:李婧，女，硕士研究生；研究方向：神经药理学
基金资助:
国家863计划基金（No.2012AA020303），长江学者和创新团队发展计划(No.PCSIRT IRT1007)，国家自然科学基金（No.81274122、No.81102831、No.81173578），国家国际科技合作项目(No.2010DFB32900)，创新药物研究开发技术平台建设（No.2012ZX09301002-004、2012ZX09103101-006），教育部博士点基金重点项目(No.20121106130001)，北京市自然基金重点项目(No.7131013)，北京市重点实验室基金（NO.BZ0150）

Progress in Studies of Glutamatergic Neurotransmission in the Pathogenesis of Depression

LI Jing^{1, 2}, SUN Jian-dong¹, YUAN Yu-he¹, CHEN Nai-hong¹

1 State Key Laboratory of Bioactive Substances and Functions of Natural Medicines, Department of Pharmacology, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100050, China
2 Tianjin University of Traditional Chinese Medicine, Tianjin, 300193, China

Online:2014-02-26 Published:2014-06-06
Contact: 陈乃宏，男，研究员，博士生导师；Tel.: +86-010-63165177，Fax: +86-010-63165177，E-mail: chennh@imm.ac.cn
About author:李婧，女，硕士研究生；研究方向：神经药理学
Supported by:
国家863计划基金（No.2012AA020303），长江学者和创新团队发展计划(No.PCSIRT IRT1007)，国家自然科学基金（No.81274122、No.81102831、No.81173578），国家国际科技合作项目(No.2010DFB32900)，创新药物研究开发技术平台建设（No.2012ZX09301002-004、2012ZX09103101-006），教育部博士点基金重点项目(No.20121106130001)，北京市自然基金重点项目(No.7131013)，北京市重点实验室基金（NO.BZ0150）

摘要/Abstract

摘要： 对抑郁症发病机制的解释主要以中枢神经系统单胺类递质的功能失调为主，然而新的研究表明除单胺类神经递质外，谷氨酸等神经递质也扮演了非常重要的角色。本文就谷氨酸循环的生理特点、其在抑郁症中可能的病理生理作用及各类针对谷氨酸异常的抗抑郁药物的治疗学进展进行综述。

关键词: 抑郁症, 谷氨酸, 抗抑郁药物

Abstract: The “monoamine hypothesis” of depression, which posits that depression is caused by decreased monoamine function in the brain, originated several decades ago. Although these monoamine-based agents are potent antidepressants, the cause of depression is far from being a simple deficiency of central monoamines. The glutamatergic system also plays important roles in the pathophysiology of major depressive disorder. This paper summarizes the physiological characteristics of glutamate in the brain, glutamatergic abnormalities in depression andantidepressants acting on the glutamatergic system.

Key words: major depressive disorder, glutamate, antidepressant

李婧孙建栋苑玉和陈乃宏. 谷氨酸能神经传递在抑郁症发病机制中的研究进展[J]. 神经药理学报, 2014, 4(1): 20-24.

LI Jing, SUN Jian-dong, YUAN Yu-he, CHEN Nai-hong. Progress in Studies of Glutamatergic Neurotransmission in the Pathogenesis of Depression[J]. Acta Neuropharmacologica, 2014, 4(1): 20-24.

参考文献

[1] Gerald W Valentine, Gerard Sanacora. Targeting glial physiology and glutamate cycling in the treatment of depression [J]. Biochem Pharmacol, 2009, 78(5): 431-439.

[2] Esra Kucukibrahimoglu, Melek Z Saygin, Mecit Caliskan, et al. The change in plasma GABA, glutamine and glutamate levels in fluoxetine- or S-citalopram-treated female patients with major depression [J]. Eur J Clin Pharmacol, 2009, 65(6): 571-577.

[3] Barbara Begni, Lucio Tremolizzo, Cristina D'Orlando, et al. Substrate-induced modulation of glutamate uptake in human platelets [J]. Br J Pharmacol, 2005, 145(6): 792-799.

[4] M J Lan, G A McLoughlin, J L Griffin, et al. Metabonomic analysis identifies molecular changes associated with the pathophysiology and drug treatment of bipolar disorder [J]. Mol Psychiatry, 2009, 14(3): 269-279.

[5] Gregor Hasler, Jan Willem van der Veen, Toni Tumonis, et al. Reduced prefrontal glutamate/glutamine and gamma-aminobutyric acid levels in major depression determined using proton magnetic resonance spectroscopy [J]. Arch Gen Psychiatry, 2007, 64(2): 193-200.

[6] Bettina Pfleiderer, Nikolaus Michael, Andreas Erfurth, et al. Effective electroconvulsive therapy reverses glutamate/glutamine deficit in the left anterior cingulum of unipolar depressed patients [J]. Psychiatry Res, 2003, 122 (3): 185-192.

[7] Gerard Sanacora, Ralitza Gueorguieva, C Neill Epperson, et al. Subtype-specific alterations of gamma-aminobutyric acid and glutamate in patients with major depression [J]. Arch Gen Psychiatry, 2004, 61(7): 705-713.

[8] Joanna M Wieronska, Beata Legutko, Dorota Dudys, et al. Olfactory bulbectomy and amitriptyline treatment influences mGlu receptors expression in the mouse brain hippocampus [J]. Pharmacol Rep, 2008, 60(6): 844-855.

[9] M Zink, B Vollmayr, P J Gebicke-Haerter, et al. Reduced expression of glutamate transporters vGluT1, EAAT2 and EAAT4 in learned helpless rats, an animal model of depression [J]. Neuropharmacology, 2010, 58(2): 465-473.

[10] J M Wieronska, P Branski, B Szewczyk, et al. Changes in the expression of metabotropic glutamate receptor 5 (mGluR5) in the rat hippocampus in an animal model of depression [J]. Pol J Pharmacol, 2001, 53(6): 659-662.

[11] Ben Ryan, Laura Musazzi, Alessandra Mallei, et al. Remodelling by early-life stress of NMDA receptor-dependent synaptic plasticity in a gene-environment rat model of depression [J]. Int J Neuropsychopharmacol, 2009, 12(4): 553-559.

[12] Ella Bossy-Wetzel, Robert Schwarzenbacher, Stuart A. Lipton. Molecular pathways to neurodegeneration [J]. Nat Med, 2004, 10 (Suppl): S2-S9.

[13] Peter Vanhoutte, Himar Bading. Opposing roles of synaptic and extrasynaptic NMDA receptors in neuronal calcium signalling and BDNF gene regulation [J]. Curr Opin Neurobiol, 2003, 13 (3): 366-371.

[14] P M Beart, R D O'Shea. Transporters for L-glutamate: an update on their molecular pharmacology and pathological involvement [J]. Br J Pharmacol, 2007, 150(1): 5-17.

[15] P V Choudary, M Molnar, S J Evans, et al. Altered cortical glutamatergic and GABAergic signal transmission with glial involvement in depression [J]. Proc Natl Acad Sci USA, 2005, 102 (43): 15653-15658.

[16] Leda S B Garcia, Clariss M Comim, Samira S Valvassori, et al. Ketamine treatment reverses behavioral and physiological alterations induced by chronic mild stress in rats [J]. Prog Neuropsychopharmacol Biol Psychiatry, 2009, 33(3): 450-455.

[17] Li Nan-xin, Liu Rong-jian, Jason M Dwyer, et al. Glutamate N-methyl-D-aspartate receptor antagonists rapidly reverse behavioral and synaptic deficits caused by chronic stress exposure [J]. Biol Psychiatry, 2011, 69(8): 754-761.

[18] 张欣, 汤颖, 王安宁, 等. 局部亚低温对大鼠脑缺血后凋亡细胞及谷氨酸转运体、亲代谢型谷氨酸受体表达的影响[J]. 临床神经病学杂志, 2007, 20: 360.

[19] Jeffrey D Rothstein, Sarjubhai Patel, Melissa R Regan, et al. Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression [J]. Nature, 2005, 433(7021): 73-77.

[20] Rita Sattler, Jeffrey D Rothstein. Targeting an old mechanism in a new disease-protection of glutamatergic dysfunction in depression [J]. Biol Psychiatry, 2007, 61(2): 137-138.

[21] M Banasr, G M Chowdhury, R Terwilliger, et al. Glial pathology in an animal model of depression: reversal of stress-induced cellular, metabolic and behavioral deficits by the glutamate-modulating drug riluzole [J]. Mol Psychiatry, 2010, 15(5): 501-511.

[22] M Smialowska, B Szewczyk, P Branski, et al. Effect of chronic imipramine or electroconvulsive shock on the expression of mGluR1a and mGluR5a immunoreactivity in rat brain hippocampus [J]. Neuropharmacology, 2002, 42(8): 1016-1023.